Topadur Pharma raises funding

Topadur Pharma develops locally acting small molecules for wound healing and fibrosis, including TOP-N53, which is in phase 2a. The non-profit DEBRA Research is investing to fund a preclinical programme against dystrophic epidermolysis bullosa.

Announced on
Round
Undisclosed round
Amount
Amount not disclosed
Location
canton of Zurich
Sector
Biotech & life sciences

Investors

  • DEBRA Research

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic